Trump’s generic drug tariff plan puts US-India pharma ties to test

A newly announced tariff schedule introduced by President Donald Trump targeting generic pharmaceutical imports is expected to significantly affect the deep trade relationship between the United States and India, which serves as the principal supplier of generic medicines to the American market.

Indian drug manufacturers currently supply roughly half of all generic pharmaceuticals consumed in the United States, with the American market generating close to a third of India’s overall pharmaceutical export earnings.

The scale of this commercial exposure means the newly outlined tariff timeline, despite featuring a two-year grace period, has immediately drawn close scrutiny from Indian pharmaceutical firms and market analysts due to the critical role US sales play in corporate revenues.

The policy introduces additional uncertainty to a bilateral trade dynamic already strained by recent tariff disputes, raising the stakes for Indian manufacturers as they decide whether to commit capital toward expanding domestic manufacturing inside the United States or absorb steep import duties in the future.

Trump outlined a phased tariff framework for generic medications entering the United States.

Under this timeline, generic drug imports will continue to enter duty-free under a zero per cent tariff until August 1, 2028, marking a two-year transition window from the policy’s effective date.

Following this grace period, a 100 per cent tariff will apply for one year, after which the import levy will rise to 200 per cent.

Trump framed the escalated duties as a penal mechanism designed to compel foreign pharmaceutical companies to construct manufacturing facilities on American soil within the allotted timeframe, rather than remaining reliant on overseas production plants.

He explicitly distinguished this new generic drug framework from the administration’s policy on branded and patented pharmaceuticals, stating that existing regulations for branded drugs would remain unchanged due to their ongoing success.

Reports citing White House details indicate that the new generic tariffs will be executed under Section 232 trade authority, matching the legal foundation used for the administration’s earlier tariffs placed on branded pharmaceuticals in April.

Trump also highlighted what he described as an unprecedented surge in new domestic pharmaceutical plant construction currently underway across the United States, presenting the new tariff schedule as a measure to reinforce an existing shift toward onshore manufacturing.

The policy holds major implications for the broader American healthcare system and global exporters because generic medications account for nearly 90 per cent of all prescriptions filled in the United States.

This action follows previous interventions in the pharmaceutical sector, including the 100 per cent tariff placed on branded drugs starting in October 2025, alongside a most-favoured-nation pricing push.

That pricing policy led more than a dozen major pharmaceutical corporations, including Pfizer, Eli Lilly, and Novo Nordisk, to conclude agreements to reduce US drug prices in exchange for multi-year exemptions from import duties.

For Indian drugmakers, the two-year transition window provides initial breathing room but lacks long-term security.

Indian generic manufacturers now face the choice of allocating capital to construct or expand production facilities within the United States before the 2028 deadline, or facing severe cost disadvantages once the punitive tariffs take effect.

Industry analysts expect to monitor whether major Indian drug companies will announce accelerated manufacturing investments in the United States over the coming months as the sector formulates its response.